Athena M. Countouriotis

2016

In 2016, Athena M. Countouriotis earned a total compensation of $1.9M as Senior Vice President and Chief Medical Officer at Halozyme Therapeutics, a 31% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$200,000
Option Awards$600,012
Salary$443,000
Stock Awards$600,002
Other$8,657
Total$1,851,671

Countouriotis received $600K in option awards, accounting for 32% of the total pay in 2016.

Countouriotis also received $200K in non-equity incentive plan, $443K in salary, $600K in stock awards and $8.7K in other compensation.

Rankings

In 2016, Athena M. Countouriotis' compensation ranked 5,242nd out of 14,075 executives tracked by ExecPay. In other words, Countouriotis earned more than 62.8% of executives.

ClassificationRankingPercentile
All
5,242
out of 14,075
63rd
Division
Manufacturing
1,886
out of 5,489
66th
Major group
Chemicals And Allied Products
598
out of 1,895
68th
Industry group
Drugs
446
out of 1,538
71st
Industry
Biological Products, Except Diagnostic Substances
78
out of 279
72nd
Source: SEC filing on March 24, 2017.

Countouriotis' colleagues

We found four more compensation records of executives who worked with Athena M. Countouriotis at Halozyme Therapeutics in 2016.

2016

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

2016

Mark Gergen

Halozyme Therapeutics

Chief Operating Officer

2016

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

2016

Harry Leonhardt

Halozyme Therapeutics

General Counsel

You may also like